Details of the Drug Combination

General Information of Drug Combination (ID: DC2VJ7T)

• Drug Combination Name: SY-1425 + Hepzato
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  SY-1425 (DMH8UF0): N.A.
  Hepzato (DM2AZPP): N.A.
• High-throughput Screening Result:
  Testing Cell Line: DU-145
  Zero Interaction Potency (ZIP) Score: 2.58
  Bliss Independence Score: 5.52
  Loewe Additivity Score: 3.37
  LHighest Single Agent (HSA) Score: 1.47

Molecular Interaction Atlas of This Drug Combination

Indication(s) of SY-1425

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[2]
Myelodysplastic syndrome	2A37	Phase 1	[2]

SY-1425 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Retinoic acid receptor alpha (RARA)	TTW38KT	RARA_HUMAN	Agonist	[2]

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Papillary renal cell carcinoma	DCGMUOJ	ACHN	Investigative	[4]
Adenocarcinoma	DC4BELG	HT29	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.